
Opinion|Videos|July 24, 2024
Updates from the CAPTIVATE Study Evaluating Ibrutinib + Venetoclax in TN CLL/SLL
Author(s)Mazyar Shadman, MD, MPH
An expert on hematologic malignancies discusses the ongoing CAPTIVATE trial evaluating ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Please briefly discuss the ongoing CAPITIVATE trial, evaluating ibrutinib plus venetoclax for the treatment of treatment naïve CLL/SLL.
- Please discuss the latest data from the CAPTIVATE trial.
- What are the key takeaways from the results of this study?
- How do the outcomes impact patients with high-risk genomic features?
- Please discuss the latest data from the CAPTIVATE trial.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
4
Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma
5



















